# Globus Medical, Inc. (GMED)

> Source: Nexqual · https://nexqual.com/GMED · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Globus Medical, Inc. (GMED), nexqual.com/GMED" · informational, not investment advice.

**Price:** USD 81.66 (+3.79% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 78.68 · day 78.46–81.83 · 52w 59.51–101.4 · market cap $11.0B · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $3.14B, net income $535M (17.0% margin), free cash flow $756M (SEC filings).
- Valuation: P/E 20.5x (avg 60.9x at the last 3 fiscal year-ends).
- 1 of 80 tracked superinvestors hold GMED (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 3 Form 4 filings, $6.4M; 3 not under a Rule 10b5-1 plan ($6.4M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.07 on a 1–5 scale) (14 analysts), mean target USD 100.92 (range 84–125).
- Total return with dividends: 1Y +30.0% vs S&P 500 +14.9%; 5Y +2.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 1.2, revenue estimate $792M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $958M | $1.02B | $1.57B | $2.52B | $2.94B | $3.14B |
| Gross profit | $719M | $759M | $1.02B | $1.48B | $1.98B | — |
| Operating income | $172M | $228M | $133M | $166M | $480M | $640M |
| Net income | $149M | $190M | $123M | $103M | $538M | $535M |
| EPS (diluted) | $1.44 | $1.85 | $1.07 | $0.75 | $3.92 | — |
| Free cash flow | $219M | $104M | $165M | $405M | $589M | $756M |
| Gross margin | 75.0% | 74.2% | 65.1% | 58.9% | 67.4% | — |
| Operating margin | 17.9% | 22.3% | 8.5% | 6.6% | 16.3% | 20.3% |
| Net margin | 15.6% | 18.6% | 7.8% | 4.1% | 18.3% | 17.0% |
| Revenue growth | +21.4% | +6.8% | +53.3% | +60.6% | +16.7% | — |
| Cash + short-term investments | $443M | $446M | $518M | $890M | $557M | — |
| Total debt | — | — | $417M | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 20.5x · P/S 3.5x · P/FCF 14.5x · P/B 2.3x · FCF yield 6.89% · Earnings yield 4.88% · Buyback yield (TTM) 2.02%
P/E at fiscal year-ends: Dec 2025 22.2x, Dec 2024 110.7x, Dec 2023 49.7x.

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold GMED. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Ruane Cunniff | Ruane Cunniff LP | 0.01% | $475K | Unchanged |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 3 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | Tobin James R | Director | 30,000 | $2.2M | 100% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-18 | Zarrilli Stephen T | Director | 25,000 | $2.2M | 100% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-06-05 | Davidar David D | Director | 25,000 | $2.0M | 3.6% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.07 on a 1–5 scale), 14 analysts; mean target USD 100.92 (low 84, high 125).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-01 | RBC Capital | Target lowered | Outperform | $115 → $85 |
| 2026-08-07 | Wells Fargo | Target lowered | Overweight | $103 → $99 |
| 2026-07-28 | UBS | Initiated | Neutral | $82 |
| 2026-07-16 | Truist Securities | Target lowered | Buy | $115 → $100 |
| 2026-07-13 | RBC Capital | Target lowered | Outperform | $120 → $115 |
| 2026-07-09 | BMO Capital | Initiated | Outperform | $94 |
| 2026-07-08 | Stifel | Target lowered | Hold | $95 → $80 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +30.0% | +2.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +30.1% | +0.4% |
| Volatility (annualized) | 45.2% | 38.7% |
| Max drawdown | -24.3% (Apr 2026→Oct 2026) | -44.7% (Oct 2021→Nov 2023) |

## Peers (Medical Devices)
GKOS (Glaukos Corporation) USD 176.69 -0.09% · PODD (Insulet Corporation) USD 148.12 +4.38% · BIO (Bio-Rad Laboratories, Inc.) USD 363.5 +0.83% · PEN (Penumbra, Inc.) USD 324.96 +0.43% · SNN (Smith & Nephew SNATS, Inc.) USD 30.88 +5.64% · TXG (10x Genomics, Inc.) USD 69.75 -7.73%

## More
Full page: https://nexqual.com/GMED · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Musculoskeletal Solutions | $763.5M | 96.7% | +7.5% |
| Enabling Technologies | $26.1M | 3.3% | -25.8% |
| Total revenue | $789.6M | 100% | — |

## Revenue by region (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| United States | $619.1M | 78.4% | +3.0% |
| International | $170.5M | 21.6% | +18.0% |
| Total revenue | $789.6M | 100% | — |

## Company outlook (8-K filed 2026-08-06)

- "The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.95 to $5.05 from the previous range of $4.70 to $4.80."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $1.20 | $1.17 | +2.3% | $792.5M | 13 |
| Next quarter (ends 2026-12-31) | $1.34 | $1.35 | -1.2% | $857.7M | 13 |
| Current fiscal year (ends 2026-12-31) | $5.00 | $4.74 | +5.4% | $3.20B | 14 |
| Next fiscal year (ends 2027-12-31) | $5.39 | $5.15 | +4.7% | $3.39B | 13 |